Last €74.15 EUR
Change Today +2.58 / 3.61%
Volume 3.0K
CG3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 2:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Open
€71.38
Previous Close
€71.57
Day High
€75.37
Day Low
€70.86
52 Week High
09/30/14 - €78.00
52 Week Low
04/15/14 - €48.55
Market Cap
59.3B
Average Volume 10 Days
3.5K
EPS TTM
--
Shares Outstanding
799.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

5,100 Employees
Last Reported Date: 02/13/14
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.3M
President and Chief Operating Officer
Total Annual Compensation: $666.7K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $645.8K
President of Hematology & Oncology
Total Annual Compensation: $753.3K
Compensation as of Fiscal Year 2013.

celgene corp (CG3) Key Developments

U.S. Food and Drug Administration Approves the Treatment of Patients with Moderate to Severe Plaque Psoriasis

Celgene Corporation announced that the U.S. Food and Drug Administration has approved OTEZLA (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. OTEZLA is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis. Psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response, affects more than 125 million people worldwide. In the ESTEEM studies, OTEZLA treatment resulted in significant and clinically meaningful improvements in plaque psoriasis as measured by PASI scores at week 16. Clinical improvement as measured by sPGA scores of clear to almost clear were also demonstrated in both studies. The safety of OTEZLA was assessed in 1,426 patients from three clinical trials. Side effects of OTEZLA were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache. Before starting OTEZLA, patients should inform their doctor if they have a history of depression or suicidal behavior and if these conditions or other mood changes develop or worsen while taking OTEZLA. Patients taking OTEZLA should have their weight checked regularly.

Switzerland Approves Celgene's Abraxane for Cancer Treatment

Celgene announced that Switzerland has approved Abraxane, the drug company's treatment for pancreatic and breast cancer.

Celgene Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014

Celgene Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Presentation Date & Speakers: Sep-22-2014, Kareem S. Reda, Director, Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €74.15 EUR +2.58

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $326.77 USD +15.36
Bristol-Myers Squibb Co $51.95 USD +1.39
Eli Lilly & Co $64.68 USD +1.58
Regeneron Pharmaceuticals Inc $381.01 USD +14.89
Shire PLC 3,848 GBp +98.00
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 53.3x
Price/Sales 10.5x
Price/Book 13.0x
Price/Cash Flow 42.6x
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.